Gold prices rebound after heavy losses; U.S.-China tensions resurface
Investing.com -- Anixa Biosciences Inc. (NASDAQ:ANIX) stock gained 2.2% in premarket trading Monday after the company announced it received a Chinese patent for its breast cancer vaccine technology.
The biotechnology firm, which focuses on cancer treatment and prevention, said the Chinese National Intellectual Property Administration issued Patent Number ZL2020800215666 covering key aspects of its breast cancer vaccine. The patent extends protection for the program into the 2040s across multiple global jurisdictions.
Anixa’s vaccine was developed in collaboration with Cleveland Clinic and targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers. The approach aims to prime the immune system to prevent tumor formation while avoiding damage to normal tissue.
"This newly issued patent further demonstrates the novelty and potential of our breast cancer vaccine," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the U.S., this patent further strengthens our ability to pursue strategic global opportunities in regions with a high incidence of breast cancer."
The company reported that a Phase 1 clinical trial of the vaccine has recently been completed, with Cleveland Clinic scheduled to present the full clinical results at the San Antonio Breast Cancer Symposium on December 11, 2025.
The patent issuance adds to Anixa’s intellectual property portfolio and provides a foundation for future international development and commercialization strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.